



Corporate Release

Lundbeck held its Annual General Meeting on 20 March 2018 at the company's registered office

Valby, Denmark, 20 March 2018 - H. Lundbeck A/S (Lundbeck) today announced that at the Annual General Meeting the report by the Board of Directors was adopted and the annual report was approved.

The proposal to distribute a dividend of 61 % of the net profit for the accounting year 2017, corresponding to DKK 8.00 per share, or a total dividend of DKK 1,592 million, was adopted.

Lars Søren Rasmussen, Lene Skole-Sørensen, Lars Erik Holmqvist and Jeremy Max Levin were re-elected to the Board of Directors. In addition, Jeffrey Berkowitz and Henrik Andersen were elected to the Board of Directors. Jens Jesper Ovesen did not stand for re-election. Immediately after the General Meeting, the Board of Directors elected Lars Søren Rasmussen as Chairman and Lene Skole-Sørensen as Deputy Chairman of the Board of Directors.

The Board of Directors of Lundbeck will hereafter comprise:

- Lars Søren Rasmussen (Chairman)
- Lene Skole-Sørensen (Deputy Chairman)
- Lars Erik Holmqvist
- Jeremy Max Levin
- Jeffrey Berkowitz
- Henrik Andersen
- Ludovic Tranholm Otterbein (employee representative)
- Jørn Møller Mayntzhusen (employee representative)
- Rikke Kruse Andreasen (employee representative)

After having elected its Chairman and Deputy Chairman, the Board of Directors appointed members for the Audit Committee, the Remuneration Committee and the Scientific Committee.

Henrik Andersen, Lars Søren Rasmussen and Lars Erik Holmqvist were elected as members of the Audit Committee. Lars Søren Rasmussen and Lene Skole-Sørensen were elected as members of the Remuneration Committee. Jeremy Max Levin, Lene Skole-Sørensen and Jeffrey Berkowitz were elected as members of the Scientific Committee.

The General Meeting approved the remuneration for the Board of Directors for the year 2018.

Deloitte Statsautoriseret Revisionspartnerselskab was re-elected as the company's auditor.



The proposal to give the Board of Directors authorization until the next annual general meeting to let the company acquire own shares of a total nominal value of up to 10% of the share capital was adopted. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on NASDAQ Copenhagen A/S at the time of the acquisition.

The Chairman of the General Meeting was authorised to file for registration the resolutions passed at the general meeting with the Danish Business Authority.

No other business was on the agenda at the Annual General Meeting.

At a Board of Directors' meeting held immediately after the Annual General Meeting the Board of Directors decided to amend Lundbeck's Articles of Association by deleting certain expired warrant programs and authorizations. The updated Articles of Association can be found at Lundbeck's web-page: www.Lundbeck.com.

The Board of Directors

Lundbeck contacts

Investors:

Palle Holm Olesen
Vice President, Investor Relations
PALO@lundbeck.com
+45 30 83 24 26

Media:

Mads Kronborg
Senior Director, Corp. Communication
MAVK@lundbeck.com
+45 36 43 40 00

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are Alzheimer's disease, depression, Parkinson's disease and schizophrenia.

Our approximately 5,000 employees in 55 countries are engaged in the entire value chain throughout research, development, manufacturing, marketing and sales. Our pipeline consists of several late-stage development programmes and our products are available in more than 100 countries. We have production facilities in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck.



Safe Harbor/Forward-Looking Statements

The above information contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance.

Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include interest rate and currency exchange rate fluctuations, delay or failure of development projects, production problems, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Lundbeck's products, introduction of competing products, Lundbeck's ability to successfully market both new and existing products, exposure to product liability and other lawsuits, changes in reimbursement rules and governmental laws and related interpretation thereof, and unexpected growth in costs and expenses.

Certain assumptions made by Lundbeck are required by Danish Securities Law for full disclosure of material corporate information. Some assumptions, including assumptions relating to sales associated with product that is prescribed for unapproved uses, are made taking into account past performances of other similar drugs for similar disease states or past performance of the same drug in other regions where the product is currently marketed. It is important to note that although physicians may, as part of their freedom to practice medicine in the US, prescribe approved drugs for any use they deem appropriate, including unapproved uses, at Lundbeck, promotion of unapproved uses is strictly prohibited.